We are seeing patients in-person and through Video Visits. Learn more about how we’re keeping you safe and please review our updated visitor policy. Please also consider supporting Weill Cornell Medicine’s efforts to support our front-line workers.

Laboratory Research

Jones Laboratory

The study of HIV has yielded both effective antiretroviral medications, and a wealth of fundamental biological insights. Our lab is striving to build upon both aspects of this legacy, through the study of HIV persistence on antiretroviral therapy. We approach this by structuring our lab into the following areas of current focus, which are intended to reinforce each other. Each area is represented by a subgroup of lab members, led by a rotating “Czar,” which meets biweekly to brainstorm, troubleshoot, and identify areas for synergy.

  • Resistance ‘Omics and Resistance Mechanisms
  • Humanized Mice
  • Clinical Studies
  • Transformative Assays

Ndhlovu Laboratory

Our mission is to understand the pathogenic mechanisms underlying complications impacting brain health and co-infections in HIV particularly among those receiving virally-suppressive antiretroviral therapy across a spectrum of ages. Using multiple immunological, virological, and molecular epigenetic and genetic modalities, we aim to exploit this knowledge in developing novel approaches and effective therapeutics to improve quality of life outcomes. We are actively engaged in pre-clinical and clinical studies nationally and internationally to achieve these goals.

Research foci:

  • HIV Neuroinflammation and CNS Reservoirs
  • Geriatric NeuroHIV
  • HIV/Co-infection

Nixon Laboratory

The Nixon lab, which includes Assistant Research Professors Matthew Bendall, Robert Furler, and Miguel de Mulder Rougvie, is interested in understanding the interaction between retroviruses and their host, including mechanisms that human host cells employ to control HIV-1 replication, and to use this knowledge towards HIV-1 cure studies. The lab is largely funded by a grant from the NIH, one of the Martin Delaney Collaboratories for the Cure of HIV. Our Collaboratory is called “Believe,” and co-led by Brad Jones and Douglas Nixon. Ongoing studies test HIV-1-specific T-cells as biosensors to measure latency reversal, and determine which combinations of LRAs are most effective in exposing latent reservoirs to recognition and elimination by cytotoxic T-cells. Other projects test the ability of innate cells to eliminate HIV infected cells, how HIV-1 induced transcription of human endogenous retroviruses (HERVs) might affect HIV-1 latency, immunometabolism and HIV latency, and how host genetics might affect HIV-1 acquisition. Finally, we are interested in how the human immune, human endogenous retroviruses, and nervous systems interact in viral infections, and in psychiatric diseases. Fellows have the opportunity to design, conduct, and analyze basic research science studies, and to develop collaborative projects in basic science with collaborators in Mexico and Brazil.

Contact Information

Infectious Diseases

Roy M. Gulick, M.D., Chief

Avi Bueno, Administrator
Tel: (212) 746-4914
Fax: (212) 746-8675
aeb3001@med.cornell.edu

Patient Appointments & Inquiries

Infectious Diseases Associates & Weill Cornell Travel Medicine
1305 York Avenue, Floor 4
New York, NY 10021
Tel: (646) 962-TRIP (8747)

Division Events

Division News

Division Publications

Clinical Trials

Related Internal Links

PDF icon Division Brochure
PDF icon Travel Clinic Brochure

Related External Links

Center for Special Studies
Clinical & Translational Science Center
Center for Global Health

Patient Care Links

Cornell Clinical Trials Unit
Weill Cornell Travel Medicine

Infectious Diseases Associates